Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Xoma Raptiva Promotions Likely To Focus On Dosing Convenience

Executive Summary

Genentech/Xoma plan to differentiate the psoriasis agent Raptiva from other biologics by highlighting Raptiva's dosing convenience
Advertisement

Related Content

Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Advertisement
UsernamePublicRestriction

Register

PS042354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel